Global Vaccines Market & Forecast Report Estimates Steady Growth by 2022 Due to Growing Immunization Coverage for HPV Vaccines

Published on : Sep 06, 2017

Albany, New York, September 6, 2017: Since many years, the rising demand for better healthcare infrastructure and high awareness levels of the benefits of immunization are the major factors for the market growth of vaccines. This is because vaccination has been approved as one of the best methods for the prevention of infectious diseases by many international organizations. Considering this growth, analysts have prepared a new study titled “Global Vaccines Market & Forecast (14 Vaccines Market, Number of People Immunized Doses of Vaccines Administered)”, which is a 318-pages report with 193 Figures and 44 Tables provides data of Global Vaccine Market (Adult & Pediatrics) along with highlights on people immunized, number of vaccine doses administered (Disease wise) & key players. The study has been freshly published to the online repository of Market Research Hub (MRH) to serve readers with accurate information regarding the future growth prospects for Vaccines market until the end of 2022.

Vaccines are given to people to help their bodies produce antibodies to protect them from a specific disease. In the first part, the study offers complete analysis of disease wise vaccine market in adults and pediatric. The research report takes into account the historical and current scenario to estimate trends of the global vaccine market in the foreseeable future. It has been analyzed that Pediatric vaccines market is having a dominant market share compared to Adult vaccines market. Looking to the overall market current scenario, the analysts predict that global vaccines market will reach US$ 60 Billion by 2022.

Moving further, the report provides insights on the market share analysis for adult and pediatric vaccine. 14 pediatric vaccines studied in the report are MMR (Measles, Mumps, and Rubella), Tap (Diphtheria, Tetanus, Pertussis), Meningitis, Haemophilus influenzae type B, Rotavirus, Travel & Miscellaneous Vaccine, Influenza, Combination Vaccine, Hepatitis, Cervical Cancer, Zoster (Shingles), Pneumonia, Polio and Varicella. Of these, Combos (Combination Vaccines) has the maximum immunization share among all pediatric vaccines for the year 2017, as they protect against more ailments in single shot, people preferring to get combination vaccine instead of a specific vaccine. By the end of 2022, Pediatric vaccines market share will be double the size of adult vaccines market share, report adds.

Besides, out of the total 9 Adult vaccines (Influenza, Cervical Cancer, Zoster, MMRV, Pneumococcal, Meningococcal, Hepatitis, TdaP, Travel) studied in the report Influenza vaccines dominates the adult vaccine market in 2017. Researchers also found that there is a consistent surge in the number of Pneumococcal and Meningococcal vaccine doses administration in future due to the rising concern about the life-threatening vaccine-preventable diseases around the world. At present, inclusion in National Immunization Schedule, growing immunization coverage for HPV Vaccines, increase in prevalence of infectious diseases, global immunization vision and strategy are some of the prime factors for this market.

The next part of the study highlights key player’s sales and forecast. GlaxoSmithKline, Sanofi Pasteur’s, Pfizer, Inc., Merck & Co. are the prime players in this market.

Request a Sample with TOC in a PDF format :

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email :

Back To Top